Johan Raud
Directeur Technique/Scientifique/R&D chez VICORE PHARMA HOLDING AB
Profil
Johan Raud is currently the Chief Scientific Officer at Vicore Pharma Holding AB since 2018.
Prior to this, he worked as an Investment Director at KI Management AB from 2000 to 2007.
He also held a Director position at Independent Pharmaceutica AB.
Dr. Raud holds a doctorate degree from Vanderbilt University and Karolinska Institutet.
Postes actifs de Johan Raud
| Sociétés | Poste | Début |
|---|---|---|
| VICORE PHARMA HOLDING AB | Directeur Technique/Scientifique/R&D | 01/01/2018 |
Anciens postes connus de Johan Raud
| Sociétés | Poste | Fin |
|---|---|---|
KI Management AB
 KI Management AB Investment ManagersFinance KI Management AB (KIM) is a venture capital investment firm located in Stockholm, on the campus of the Karolinska Institute. They are the investment advisor and manager of the Karolinska Investment Fund KB (KIF). The fund was established in 1999 by the Karolinska Institute and Alecta, a Nordic pension plan. KIM has a partnership agreement with Karolinska Innovations AB, a technology transfer entity of the Karolinska Institute. The Karolinska Institute, founded in 1810, has a medical focus and is responsible for selecting the winner of the Nobel Prize in Physiology or Medicine. | Private Equity Investor | 31/12/2007 |
Independent Pharmaceutica AB
 Independent Pharmaceutica AB Medical DistributorsDistribution Services Independent Pharmaceutica AB is a privately owned company. The major owners are Karolinska Investment Fund, LH Advisory, Sandin &Co and The Foundation for Baltic and East European Studies (Östersjöstiftelsen). Independent Pharmaceutica aims to provide pharmacological solutions for treatment of nicotine addiction. The company is spun out of research from the Karolinska Institutet in Stockholm, Sweden. Tobacco use is the leading preventable cause of morbidity and premature death in the world.Currently over 1.2 billion people smoke worldwide and the number of annual deaths from tobacco-related diseases is over 4 million and rising. The costs for society are huge. With the new vaccine Niccine® against nicotine addiction, the health condition of millions of patients is expected to be improved. | Directeur/Membre du Conseil | - |
Formation de Johan Raud
| Karolinska Institutet | Doctorate Degree |
| Vanderbilt University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VICORE PHARMA HOLDING AB | Health Technology |
| Entreprise privées | 2 |
|---|---|
KI Management AB
KI Management AB Investment ManagersFinance KI Management AB (KIM) is a venture capital investment firm located in Stockholm, on the campus of the Karolinska Institute. They are the investment advisor and manager of the Karolinska Investment Fund KB (KIF). The fund was established in 1999 by the Karolinska Institute and Alecta, a Nordic pension plan. KIM has a partnership agreement with Karolinska Innovations AB, a technology transfer entity of the Karolinska Institute. The Karolinska Institute, founded in 1810, has a medical focus and is responsible for selecting the winner of the Nobel Prize in Physiology or Medicine. | Finance |
Independent Pharmaceutica AB
Independent Pharmaceutica AB Medical DistributorsDistribution Services Independent Pharmaceutica AB is a privately owned company. The major owners are Karolinska Investment Fund, LH Advisory, Sandin &Co and The Foundation for Baltic and East European Studies (Östersjöstiftelsen). Independent Pharmaceutica aims to provide pharmacological solutions for treatment of nicotine addiction. The company is spun out of research from the Karolinska Institutet in Stockholm, Sweden. Tobacco use is the leading preventable cause of morbidity and premature death in the world.Currently over 1.2 billion people smoke worldwide and the number of annual deaths from tobacco-related diseases is over 4 million and rising. The costs for society are huge. With the new vaccine Niccine® against nicotine addiction, the health condition of millions of patients is expected to be improved. | Distribution Services |
